Corvus Pharmaceuticals, Inc. Gains 165.96%
Tue, Jan 20, 2026 at 07:15 PM
Corvus Pharmaceuticals, Inc. (CRVS:NASDAQ) shot up at $21.41, representing a gain of 166%. On Tue, Jan 20, 2026, CRVS:NASDAQ touched a New 2-Week High of $21.41. The stock got featured on our News Catalysts scanner on Tue, Jan 20, 2026 at 05:01 PM in the 'PUBLIC OFFERING' category. From Tue, Jan 06, 2026, the stock recorded 55.56% Up Days and 50.00% Green Days
About Corvus Pharmaceuticals, Inc. (CRVS:NASDAQ)
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company. It is engaged in development and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells.
Top 10 Gainers:
- INVO Fertility, Inc. (IVF:NASDAQ), 191.73%
- Corvus Pharmaceuticals, Inc. (CRVS:NASDAQ), 165.96%
- Pheton Holdings Ltd (PTHL:NASDAQ), 105.16%
- Aclaris Therapeutics, Inc. (ACRS:NASDAQ), 69.08%
- RAPT Therapeutics, Inc. (RAPT:NASDAQ), 64.02%
- Signing Day Sports, Inc. (SGN:NYSEMKT), 61%
- Youlife Group Inc. (YOUL:NASDAQ), 59.93%
- Top Wealth Group Holding Limited (TWG:NASDAQ), 54.31%
- Lulu's Fashion Lounge Holdings, Inc. (LVLU:NASDAQ), 42.28%
- Lottery.com Inc. (SEGG:NASDAQ), 42.19%